About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1/2NCT03477019

Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer

The aim of this clinical trial is to investigate whether the therapeutic response of chemotherapy can be improved by focused ultrasound and microbubbles. Patients with liver metastases from breast can...

Lead sponsor: St. Olavs Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

St. Olavs Hospital

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Histologically verified breast carcinoma or colorectal carcinoma
•2 or multiple liver metastases
•considered eligible by a consulting oncologist for first line treatment with chemotherapy in the group of taxanes (patients with breast cancer) or the combination regimen FOLFIRI (patients with colorectal carcinoma)
•Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations

Exclusion Criteria

•Known contraindications for ultrasound contrast-enhancement agent Sonovue® (Bracco)
•Hematological bleeding status before experimental treatment: Hb \< 8g/dL, trc \< 80 x109/l, APTT˃ 45s, INR ˃ 1,5
•Considered eligible for surgical removal of liver metastases
•Pregnancy

Related studies

RECRUITINGPhase 2

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098 · Breast Neoplasms

RECRUITINGPhase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319 · Colorectal Neoplasms, Gastrointestinal Neoplasms

Impact of SMS Messaging on Participation in Colorectal Cancer Screening

NCT07628998 · Colorectal Neoplasms, Early Detection of Cancer

Early Detection of Advanced Adenomas and Colorectal Cancer

NCT06342440 · Colorectal Cancer, Colorectal Neoplasms, and more

RECRUITINGPhase 2

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 19, 2023Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment17

Start dateNov 2018

Last updatedJan 19, 2023

Condition

Colorectal Neoplasms Breast Neoplasms

Locations shown

St.Olavs Hospital

Trondheim

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 19, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions